Graphite Bio’s Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish
A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc.
Morgan Stanley Initiates Coverage On Graphite Bio with Overweight Rating, Announces Price Target of $35
Morgan Stanley analyst Jeffrey Hung initiates coverage on Graphite Bio (NASDAQ:GRPH) with a Overweight rating and announces Price Target of $35.
B of A Securities Initiates Coverage On Graphite Bio with Buy Rating, Announces Price Target of $35
B of A Securities initiates coverage on Graphite Bio (NASDAQ:GRPH) with a Buy rating and announces Price Target of $35.
Cowen & Co. Initiates Coverage On Graphite Bio with Outperform Rating
Cowen & Co. analyst Phil Nadeau initiates coverage on Graphite Bio (NASDAQ:GRPH) with a Outperform rating.
SVB Leerink Initiates Coverage On Graphite Bio with Outperform Rating, Announces Price Target of $34
SVB Leerink analyst Mani Foroohar initiates coverage on Graphite Bio (NASDAQ:GRPH) with a Outperform rating and announces Price Target of $34.
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks.
There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.
Stocks That Hit 52-Week Highs On Wednesday
This morning 132 companies reached new 52-week highs.